Posted 23 February 2016
By Kwee-Tat Chew, MBA, BPharm, Rao Meenakshi, PhD, RAC
This article discusses misconceptions and their causes, surrounding drug development in Asia, and explains the regions current drug development landscape.
Share this article:
Categories: Biologics and biotechnology, Drugs, Clinical, Submission and registration, Features, Japan, China, Korea, Asean, MHLW, PMDA, CFDA, MFDS, ICH, APEC
Tags: Data exclusivity, tripartite cooperation on clinical research, Tripartite Working Group, TRIPS, ICH-E5, APEC, ASEAN, Biosimilars